Home › Enable Bio to Participate in NIH Program to Commercialize Technologies

Enable Bio to Participate in NIH Program to Commercialize Technologies

Oct 10, 2018

NEW YORK (360Dx) – Enable Biosciences said on Tuesday that it has been selected to participate in a National Institutes of Health program to help small healthcare and life science companies bring their products to market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
14
Featured Webinar

A Multiomics Approach to Defining the Nature of Early Malignant Transformations of the Immune System

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

What's Popular?

In Immunoassays

  1. Genspeed, Virogates Partner on Medical Risk Classification Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.